Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLUME study of PET-based metabolic tumor volume stratification in first-line nivolumab + ipilimumab-treated advanced NSCLC
jRCT1031260283Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: 6-month progression-free survival rate. Started Aug 2026; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031260283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260283.